All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: tni.ohw@snoissimrep).
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
Excerpt
The World Health Organization (WHO) first published guidance for national tuberculosis control programmes on managing tuberculosis in children (hereafter called “the Guidance”) in 2006. The Guidance follows the principles of a public health approach aimed at optimizing outcomes, including the quality of life and survival, of children with tuberculosis; it also serves as a reference tool for countries to adopt and adapt according to their national circumstances.
During 2009 and 2010, WHO updated the Guidance through a series of coordinated efforts to review and synthesize evidence on the correct dosages of antituberculosis medicines for use in children and the regimens that should be used for different manifestations of the disease in children. This evidence was assembled following systematic reviews, pharmacokinetic simulations and the preparation of evidence summaries, using GRADE profiles and analysis where appropriate.
There have been major developments in advancing the use of new diagnostic tools, but these tools are not recommended for the diagnosis of latent tuberculosis infection or active tuberculosis disease in children. Preventive chemotherapy for children infected with the human immunodeficiency virus (HIV) will be addressed in other guidelines published by WHO.
The availability of new evidence, specifically concerning the correct dosages of the four essential antituberculosis medicines, justified the rapid revision of WHO’s Guidance.
Representatives of the Stop TB Partnership’s Childhood TB sub-working group who participated in the Guidelines Group formulated this revised guideline in the format of a Rapid Advice during a meeting of the Guidelines Group held in March 2010. In addition, two experts in paediatric pharmacology contributed to the development of this Rapid Advice.
Contents
- Acknowledgements
- 1. Overview
- 2. Recommendations at a glance
- 3. Revision process
- 4. Dissemination, adaptation, implementation and evaluation
- 5. Companion documents
- 6. Collaboration with external partners
- 7. Key recommendations
- 8. Research needs
- 9. Members of the Guidelines Group
- 10. Members of the External Review Group
- 11. Declarations of interest
The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.
The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.
- NLM CatalogRelated NLM Catalog Entries
- API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.[J Assoc Physicians India. 2006]API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.API Consensus Expert Committee. J Assoc Physicians India. 2006 Mar; 54:219-34.
- Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention.[MMWR Recomm Rep. 1998]Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention.. MMWR Recomm Rep. 1998 Oct 30; 47(RR-20):1-58.
- A refined symptom-based approach to diagnose pulmonary tuberculosis in children.[Pediatrics. 2006]A refined symptom-based approach to diagnose pulmonary tuberculosis in children.Marais BJ, Gie RP, Hesseling AC, Schaaf HS, Lombard C, Enarson DA, Beyers N. Pediatrics. 2006 Nov; 118(5):e1350-9.
- Review [Development of antituberculous drugs: current status and future prospects].[Kekkaku. 2006]Review [Development of antituberculous drugs: current status and future prospects].Tomioka H, Namba K. Kekkaku. 2006 Dec; 81(12):753-74.
- Review Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF Assay for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children: Policy Update[ 2013]Review Automated Real-Time Nucleic Acid Amplification Technology for Rapid and Simultaneous Detection of Tuberculosis and Rifampicin Resistance: Xpert MTB/RIF Assay for the Diagnosis of Pulmonary and Extrapulmonary TB in Adults and Children: Policy Update. 2013
- Rapid AdviceRapid Advice
- XP_006504616 OR NP_034442 (2)Protein
- hypothetical protein BG259_26800 [Vibrio harveyi]hypothetical protein BG259_26800 [Vibrio harveyi]gi|1120758401|gb|APP08835.1||gnl|PR 0970|BG259_26800Protein
- sigma-54-dependent Fis family transcriptional regulator [Vibrio anguillarum]sigma-54-dependent Fis family transcriptional regulator [Vibrio anguillarum]gi|1447673618|gnl|PRJNA454362|DEB41 0|gb|AXN15415.1|Protein
- Homologene neighbors for GEO Profiles (Select 93748582) (0)GEO Profiles
Your browsing activity is empty.
Activity recording is turned off.
See more...